DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 02:08:21 2024-06-05 pm EDT | After market 03:00:47 pm | |||
| 348.4 EUR | +0.69% |
|
348.2 | -0.07% |
| Current month | +0.54% | ||
| 1 month | +4.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 348.4 | +0.69% |
| 24-06-04 | 346.1 | +0.17% |
| 24-06-03 | 345.5 | +0.37% |
| 24-05-31 | 344.2 | +0.91% |
| 24-05-30 | 341.1 | -0.60% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 02:08 pm EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG1BT1 |
| ISIN | DE000MG1BT10 |
| Date issued | 2024-04-02 |
| Maturity | 2025-03-21 (289 Days) |
| Parity | 1 : 1 |
| Emission price | 331.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 348.4 € |
|---|---|
| Lowest since issue | 324.5 € |
| Spread | 0.32 € |
| Spread % | 0.09% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Certificates
- Certificat
